References
- Cunningham FG, Hauth JC, Leveno KJ, et al. Hypertensive disorders in pregnancy. In: Cunningham FG, Leveno KJ, Bloom SL, et al., eds. Williams obstetrics. 22nd ed. Connecticut: McGraw-Hill Companies; 2005:761–808
- Habli M, Sibai BM. Hypertensive disorders of pregnancy. In: Gibbs RS, Karlan BY, Haney AF, Nygaard IE, eds. Danforth’s obstetrics and gynecology. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:257–71
- Eide IP, Isaksen CV, Salvesen KA, et al. Decidual expression and maternal serum levels of heme oxygenase 1 are increased in preeclampsia. Acta Obstet Gynecol Scand 2008;87:272–9
- Serdar Z, Gür E, Develioğlu O. Serum iron and copper status and oxidative stress in severe and mild preeclampsia. Cell Biochem Funct 2006;24:209–15
- Holmes VA, McCance DR. Could antioxidant supplementation prevent pre-eclampsia? Proc Nutr Soc 2005;64:491–501
- Villar J, Purwar M, Merialdi M, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009;116:780–8
- D'Anna R, Baviera G, Corrado F, et al. Neurokinin B and nitric oxide plasma levels in preeclampsia and isolated intrauterine growth restriction. Br J Obstet Gynaecol 2004;111:1046–50
- Conrad KP, Vernier KA. Plasma level, urinary excretion and metabolic production of cGMP during gestation in rats. Am J Physiol 1989;257:R847–53
- Endemann D, Schiffrin E. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983–92
- Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824–33
- Dekker GA, Sibai BM. Early detection of preeclampsia. Am J Obstet Gynecol 1991;165:160–72
- Mao D, Che J, Li K, et al. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia. Arch Gynecol Obstet 2010;282:371–5
- Lopez-Alarcon M, Montalvo-Velarde I, Vital-Reyes VS, et al. Serial determinations of asymmetric dimethylarginine and homocysteine during pregnancy to predict pre-eclampsia: a longitudinal study. BJOG 2015;122:1586–92
- Speer PD, Powers RW, Frank MP, et al. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008;198:112.e1–7
- Laskowska M, Laskowska K, Oleszczuk J. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiopathogenesis of preeclampsia and/or intrauterine fetal growth restriction. J Matern Fetal Neonatal Med 2015;28:26–32
- Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003;4:33–40
- Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998;178:551–6
- Fickling SA, Williams D, Vallance P, et al. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and preeclampsia. Lancet 1993;342:242–3
- Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998;77:808–13
- Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentration of asymmetric dimethylarginine in pregnant woman who subsequently develop preeclampsia. Lancet 2003;361:1511–17
- Tsukahara H, Ohta N, Tokuriki S, et al. Determination of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in umbilical blood. Metab Clin Exp 2008;57:215–20